IMC 002
Alternative Names: Anti-CD47 mAb - ImmuneOncia Therapeutics; IMC-002Latest Information Update: 10 Jun 2025
At a glance
- Originator ImmuneOncia Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Macrophage stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lymphoma; Solid tumours
Most Recent Events
- 02 Jun 2025 Efficacy and safety data from a phase Ib trial in Solid tumours released by ImmuneOncia
- 03 Jun 2024 Efficacy and pharmacodynamics data from a phase I trial in Solid tumors released by ImmuneOncia
- 09 May 2024 IMC 002 is still in I trials for Lymphoma (Second-line therapy or greeter) and Solid tumours (Metastatic disease, Late-stage disease) in USA and South Korea (NCT04306224)